Key points for investors:
- Strong Q1 2026 financial results: total revenue $174.7M, up 6.2% y/y (8.7% ex-sold graduate schools); adjusted EBITDA $29.2M, up 37.5% y/y; diluted EPS $0.94, up ~129% y/y. Results beat guidance.
- Guidance: Company left full-year 2026 revenue and adjusted EBITDA guidance in place but raised full-year diluted EPS guidance (midpoint implies ~85% increase vs. 2025). Q2 guidance: revenue $170–172M, adjusted EBITDA $16.5–18M, EPS $0.34–0.39. Full-year guidance: revenue $686–696M, adjusted EBITDA $93–102M, diluted EPS $2.33–2.68.
- Segment performance: Health Plus (nursing/health) revenue +11% y/y driven by ~8% enrollment growth and a modest tuition increase; continued campus expansion (Orlando open, Detroit planned Q1 2027). Military Plus revenue +6.5% y/y with ~4% registration growth; Military Plus delivered ~36% adjusted EBITDA margin in Q1.
- Near-term headwinds: Active-duty registration softness in Navy, Air Force and Marines tied to Middle East deployments (timing disruption rather than structural demand), partially offset by high‑teens growth in veterans & family registrations. Management expects partial recovery in Q2 and further recovery in Q3.
- Mitigation and investments: Company is deploying incremental marketing (~$2.2M incremental in Q2) toward veterans & family segments to offset deployment impacts. Continued investment in tech/platform consolidation (post-institutional combination) and campus Trailblazer openings; tuck‑in M&A remains a priority.
- Institutional combination: Higher Learning Commission approved consolidation of institutions into a single accredited entity (American Public University System). Dept. of Education approval and APEI demerger remain the final step; target effective date is early Q3 2026. Expected material revenue synergies are anticipated to begin in 2027; limited near-term expense benefit as shared services already in place.
- Strong balance sheet & capital allocation: Cash, cash equivalents and restricted cash $221M (Mar 31), total debt $90M; excess cash over debt ~$131M. Board authorized $50M share repurchase program; first-quarter buybacks modest. Company signals flexibility for organic growth, campus openings, tuck-in M&A and opportunistic capital returns.
- Other notes: Q1 benefited from some one-time tax benefits tied to stock appreciation; tax rate expected to normalize. Health Plus had some year-over-year timing differences related to instructional materials in the prior year. Management reiterates a multi-year plan targeting ~$890–925M organic revenue by 2029 and margin expansion toward ~20%+ adjusted EBITDA margins over the plan horizon.
Sign In
Buy APEI
